Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 55
Filtrar
Más filtros

Intervalo de año de publicación
1.
Nanotechnology ; 32(41)2021 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-34285145

RESUMEN

This study focuses on the development of a new hybrid biological material to be applied in the production of electrical energy. These organo-metallic cells are constituted by cyanobacteria (Fischerella muscicola) and silver nanoparticles (AgNPs). AgNPs were obtained by green synthesis using the extract of the fruit of theBerberis halliiplant as reducing agent with two different concentrations of silver nitrate (AgNO3), 1 and 10 mM. The morphology, physicochemical and electrical properties of the cyanobacteria with and without AgNPs were evaluated. To verify the efficacy of this new material, and the effect of the medium used, Nitrofoska or BG-11, the growth kinetics was evaluated by UV-vis up tot= 63 d with and without renewal of the culture medium and O2/CO2exchange. Through morphological characterizations ofFischerella muscicolait was possible to identify the presence of an associated bacterium identified using molecular techniques asPseudomona guguanensithat could act as a supporting organism in the growth of this cyanobacteria. The studies carried out did not shown cell toxicity for the cultures that have AgNPs and on the other hand, it was observed that the hybrid cells (Cy-AgNPs) are electron carriers recording an increase of up to 57% and 18% in their electrical potential with BG-11 and Nitrofoska culture media, respectively and an increase in the anodic current peak of 6.5% of Cy-AgNPs respect to onlyF. musicola.

2.
Int J Obes (Lond) ; 39(2): 279-87, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24675715

RESUMEN

BACKGROUND: Obesity severely affects human health, and the accompanying non-alcoholic fatty liver disease (NAFLD) is associated with high morbidity and mortality. Rapid and non-invasive methods to detect this condition may substantially improve clinical care. METHODS: We used liquid and gas chromatography-quadruple time-of-flight-mass spectrometry (LC/GC-QTOF-MS) analysis in a non-targeted metabolomics approach on the plasma from morbidly obese patients undergoing bariatric surgery to gain a comprehensive measure of metabolite levels. On the basis of these findings, we developed a method (GC-QTOF-MS) for the accurate quantification of plasma α-ketoglutarate to explore its potential as a novel biomarker for the detection of NAFLD. RESULTS: Plasma biochemical differences were observed between patients with and without NAFLD indicating that the accumulation of lipids in hepatocytes decreased ß-oxidation energy production, reduced liver function and altered glucose metabolism. The results obtained from the plasma analysis suggest pathophysiological insights that link lipid and glucose disturbances with α-ketoglutarate. Plasma α-ketoglutarate levels are significantly increased in obese patients compared with lean controls. Among obese patients, the measurement of this metabolite differentiates between those with or without NAFLD. Data from the liver were consistent with data from plasma. Clinical utility was assessed, and the results revealed that plasma α-ketoglutarate is a fair-to-good biomarker in patients (n=230). Other common laboratory liver tests used in routine application did not favourably compare. CONCLUSION: Plasma α-ketoglutarate is superior to common liver function tests in obese patients as a surrogate biomarker of NAFLD. The measurement of this biomarker may potentiate the search for a therapeutic approach, may decrease the need for liver biopsy and may be useful in the assessment of disease progression.


Asunto(s)
Ácidos Cetoglutáricos/sangre , Metaboloma , Enfermedad del Hígado Graso no Alcohólico/sangre , Obesidad Mórbida/sangre , Biomarcadores/sangre , Cromatografía Liquida , Progresión de la Enfermedad , Humanos , Metabolismo de los Lípidos , Espectrometría de Masas , Metabolómica/métodos , Enfermedad del Hígado Graso no Alcohólico/etiología , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/fisiopatología , Obesidad Mórbida/complicaciones , Obesidad Mórbida/metabolismo , Obesidad Mórbida/fisiopatología , Valor Predictivo de las Pruebas
3.
Transplant Proc ; 40(9): 2936-40, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19010153

RESUMEN

Immunosuppression after organ transplantation is associated with a markedly increased risk of nonmelanoma skin cancer (NMSC) and malignancies, including posttransplant lymphoproliferative disorder (PTLD) and solid organ cancer. This study sought to investigate the incidence of malignancies and the clinical characteristics and risk factors of the renal transplant patients with solid organ tumors and NMSC. We included 1017 patients who received a kidney transplant in our hospital from 1979 to 2007. Results were contrasted with a cohort of patients from the same center without malignancies. The mean follow-up of patients in our series was 10 years. The mean age at presentation of the malignancy was 61 +/- 5 years. The malignancy and NMSC incidences were 6% and 5%, respectively. Patients with malignancy had a longer posttransplant time and greater recipient and donor age. In the multivariate analysis, independent risk factors for developing NMSC were: male sex (hazard ratio [HR] 3.1, P = .004); greater patient age (HR 1.09, P < .001), longer posttransplant time (HR 1.2, P = .004) and tacrolimus treatment (HR 4.4, P = .001). Risk factors associated with developing any malignancy were: patient age (HR 1.06, P < .001), number of grafts (HR 3.2, P = .019), tacrolimus treatment (HR 2.5, P = .035), and time posttransplantation (HR 1.2, P = .011). The mean times to development of an NMSC, solid organ malignancy, on PTLD were 7.5, 6.1, or 3.9 years, respectively. The mean survival time from the diagnosis of any malignancy was 9.6 months (95% confidence interval, 0.12-30) for solid organ malignancies and 1 month (95% confidence interval, 0.24-1.87) for PTLD.


Asunto(s)
Trasplante de Riñón/efectos adversos , Neoplasias/epidemiología , Factores de Edad , Anciano , Femenino , Estudios de Seguimiento , Humanos , Trasplante de Hígado/efectos adversos , Masculino , Persona de Mediana Edad , Neoplasias/mortalidad , Trasplante de Páncreas/efectos adversos , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Factores de Riesgo , Caracteres Sexuales , Análisis de Supervivencia , Factores de Tiempo
4.
Obes Surg ; 28(10): 3259-3267, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-29961179

RESUMEN

AIM: Laparoscopic gastric plication (LGP) is a bariatric surgical technique based on the anatomical principles of laparoscopic sleeve gastrectomy (LSG), but its effects on the metabolic profile are still uncertain. The aim of our study is to compare the changes in weight, metabolic parameters and gastric histology following intervention by gastric plication (GP) and sleeve gastrectomy (SG) in an experimental model of obesity. METHODS: To conduct the study, 32 8-week-old male Sprague-Dawley rats (Charles River®) were fattened by means of a cafeteria diet and randomly assigned to the following experimental groups: group 1: GP (n = 12); group 2: SG (n = 12) and group 3: sham (n = 8). RESULTS: Unlike the SG group, the GP group attained the weight of the sham group at the end of the experiment (week 16). The GP group continued to eat more cafeteria diet than the SG group. In addition, the SG group achieved better glycaemic control than the GP group. Significantly higher plasma ghrelin levels were observed at week 16 in the GP group than in the SG group (2.29 ± 0.5 vs 1.07 ± 0.4, p < 0.05), which also occurred for the glucagon plasmatic levels (62.71 ± 36.2 vs 24.63 ± 9.3, p < 0.05). CONCLUSIONS: GP is not as effective as SG and cannot be considered a metabolic surgery due to observed hormonal variations. The animals subjected to a GP continued to have a high appetite for the cafeteria diet unlike the animals submitted to an SG. Hormonal mechanisms possibly related to glucagon and ghrelin may be involved in this metabolic response.


Asunto(s)
Ingestión de Energía/fisiología , Gastrectomía/métodos , Obesidad/metabolismo , Obesidad/cirugía , Estómago/cirugía , Pérdida de Peso/fisiología , Animales , Glucemia/metabolismo , Dieta Alta en Grasa , Modelos Animales de Enfermedad , Ghrelina/sangre , Glucagón/sangre , Laparoscopía/métodos , Masculino , Obesidad/etiología , Obesidad/patología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley
5.
J Clin Invest ; 91(6): 2754-60, 1993 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8514883

RESUMEN

In septic shock, hypotension, disseminated intravascular coagulation, and neutrophil activation are related to the activation of the blood coagulation contact system. This study evaluates in dogs the effect of the C1-esterase inhibitor (C1-INH), a main inhibitor of the blood coagulation contact system, on the cardiovascular and respiratory dysfunction associated with endotoxic shock. Two groups were included: controls, which received Escherichia coli endotoxin, and a C1-INH group in which C1-INH was infused before E. coli endotoxin administration. In both groups, endotoxin produced hypodynamic shock; however, the decrease in the systolic index and the ventricular systolic work indexes were greater in controls than the C1-INH group. In controls, the arterial O2 partial pressure decreased by 30% and the alveolo-arterial O2 difference increased by 625%, these parameters remained unchanged in the C1-INH group. Hypoxemia was associated with increased intrapulmonary shunt, decreased blood coagulation contact factors, and decreased C3c. In contrast, C1-INH administration prevented endotoxin-induced hypoxemia, the increase in intrapulmonary shunt, and the decrease in blood coagulation contact factors. This study shows that, in dogs with endotoxic shock, pulmonary dysfunction is associated with an activation of the blood coagulation contact phase system. An inhibition of this system by C1-INH prevented the hypoxemia induced by endotoxic shock.


Asunto(s)
Proteínas Inactivadoras del Complemento 1/farmacología , Endotoxinas/farmacología , Corazón/fisiopatología , Pulmón/fisiopatología , Choque Séptico/fisiopatología , Animales , Complemento C3c/análisis , Perros , Factor XI/análisis , Factor XII/análisis , Hemodinámica , Humanos , Hipoxia/prevención & control , Recién Nacido , Precalicreína/análisis , Choque Séptico/tratamiento farmacológico
6.
Transplant Proc ; 39(7): 2167-9, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17889126

RESUMEN

INTRODUCTION: Renal function predicts graft survival in kidney transplant patients. This study compared the 2-year evolution of renal function in patients treated with cyclosporine or tacrolimus in combination with mycophenolate mofetil (MMF) and prednisone. METHODS: We studied 1558 cadaveric renal transplant recipients from 14 Spanish hospitals between January 2000 and December 2002. Of these, 1168 were treated with tacrolimus and 390 with cyclosporine. The primary efficacy endpoint was long-term renal function. Renal function was measured by serum creatinine and glomerular filtration rate (GFR) by creatinine clearance calculated from the Cockcroft-Gault formula. This report summarizes the 2-year results. RESULTS: At 24 months the tacrolimus group showed significantly better serum creatinine (1.5 +/- 0.7 vs 1.8 +/- 0.8 mg/dL, P < .001) and GFR (60.5 +/- 20.9 mL/min vs 47.9 +/- 10.0, P < .001) than the cyclosporine group. Additionally, recipients with ideal graft donors (23.5 +/- 2.8 vs 24.0 +/- 2.9 years) had a better serum creatinine at 2 years (1.23 +/- 0.2 vs 1.5 +/- 0.4 mg/dL, P < .05). Multivariate analysis showed that tacrolimus was an independent factor associated with better renal function: odds ratio 1.6, 95% confidence interval (1.2 to 2.2), P < .001. CONCLUSIONS: Patients with a renal transplant treated with tacrolimus in combination with MMF and prednisone displayed better renal function at 2 years than those who received cyclosporine.


Asunto(s)
Ciclosporina/uso terapéutico , Pruebas de Función Renal , Trasplante de Riñón/fisiología , Tacrolimus/uso terapéutico , Adulto , Anciano , Cadáver , Femenino , Humanos , Inmunosupresores/uso terapéutico , Trasplante de Riñón/inmunología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Donantes de Tejidos
7.
Obes Surg ; 27(11): 2836-2844, 2017 11.
Artículo en Inglés | MEDLINE | ID: mdl-28478583

RESUMEN

INTRODUCTION: Laparoscopic sleeve gastrectomy is one of the most common techniques in bariatric surgery, but there is no consensus on the optimal distance from the pylorus to start the gastric transection. The aim of this study is to determine the differences in gastric emptying, gastric distension and metabolic response between two starting distances. MATERIAL AND METHODS: This is a prospective randomised study of 60 patients (30 patients with the section at 3 cm and 30 patients at 8 cm from the pylorus). We calculate at 6 and 12 months from surgery gastric emptying by scintigraphy (T1/2 min), gastric volume by CT scan (cc) and metabolic response by blood sample analysis (glucose, HbA1c, insulin, HOMA-IR, GLP-1, GIP and C-peptide). RESULTS: Gastric emptying increases the speed significantly in both groups but is greater in the 3-cm group (p < 0.05). Dividing groups into type 2 diabetic patients and non-diabetic patients, the speed in non-diabetic patients is significantly higher for the 3-cm group. Residual volume increases significantly in both groups, and there are no differences between them. One year after surgery, there are significant improvements in the hyperinsulinaemia in the patients of the 3-cm group with respect to the 8-cm group, but only in diabetic patients. No differences between groups are found regarding changes in GLP-1 or GIP. CONCLUSIONS: Gastric emptying is faster in patients with antrum resection. The distance does not influence the gastric emptying of diabetic patients. Other mechanisms may explain metabolic response besides GLP-1 and its association with improvements in diabetes via gastric emptying.


Asunto(s)
Gastrectomía/rehabilitación , Vaciamiento Gástrico/fisiología , Laparoscopía/rehabilitación , Obesidad Mórbida/rehabilitación , Obesidad Mórbida/cirugía , Adulto , Anciano , Péptido C/sangre , Femenino , Gastrectomía/efectos adversos , Gastrectomía/métodos , Péptido 1 Similar al Glucagón/sangre , Glucosa/metabolismo , Humanos , Insulina/metabolismo , Laparoscopía/efectos adversos , Laparoscopía/métodos , Masculino , Persona de Mediana Edad , Obesidad Mórbida/metabolismo , Obesidad Mórbida/fisiopatología , Tamaño de los Órganos , Estudios Prospectivos , Píloro/fisiología , Píloro/cirugía , Estómago/diagnóstico por imagen , Estómago/patología
8.
Transplant Proc ; 38(10): 3530-2, 2006 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17175323

RESUMEN

The purpose of this study was to investigate the incidence and risk factors for the development of diabetes mellitus after kidney transplantation (PTDM). A total of 1783 nondiabetic renal allograft recipients transplanted from January 2000 to December 2002 were included. Diabetes was diagnosed following American Diabetes Association criteria. While 1276 patients were treated with tacrolimus (Tac), mycophenolate mofetil (MMF), and steroids, 507 patients received cyclosporine-ME (CsA), MMF, and steroids. PTDM incidence at 6, 12, and 24 months was 14.2%, 12.8%, and 13.3%, respectively. Cumulative incidence during the follow-up was 21.6%. Only 121 of the diabetic patients (47.6%) at 6 months remained diabetic at 24 months. Furthermore, 60 patients of 116 patients on insulin at 6 months (51.7%) remained on treatment at 24 months. The cumulative incidence of PTDM was similar in the two immunosuppressive treatments (19.7% on CsA-MMF vs 22.3% on Tac-MMF; P = NS). However, at 24 months, 14 of 50 diabetic patients on CsA-MMF (28%) and 74 of 161 patients on Tac-MMF (45.9%) were on insulin treatment (P < .05). By Cox regression analysis, age older than 60 years (RR 1.61; 95%CI 1.28-2.04; P < .001), body mass index (BMI) > 30 kg/m2 at transplantation (RR 1.66; 95%CI 1.27-2.16; P < .001), and immunosuppression with Tac (RR 1.30; 95%CI 1.02-1-66; P = .033) were associated with PTDM. In conclusions, the incidence of PTDM at 24 months in immunosuppressive protocols including MMF is about 22%, and it is associated with older age, increased BMI, and immnunosuppression with Tac.


Asunto(s)
Diabetes Mellitus/epidemiología , Trasplante de Riñón/efectos adversos , Corticoesteroides/uso terapéutico , Adulto , Índice de Masa Corporal , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Inmunosupresores/uso terapéutico , Incidencia , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/epidemiología , Estudios Prospectivos , Factores de Tiempo , Trasplante Homólogo
9.
Nefrologia ; 26(5): 609-14, 2006.
Artículo en Español | MEDLINE | ID: mdl-17117905

RESUMEN

Acute renal rejection repeatedly activates immunocompromised CD8 + T cells. Maintained activation of CD8 + T cells can induce a process of replicative senescence. In the present study, we will evaluate in CD8 lymphocytes from patients undergoing acute renal rejection characteristics of replicative senescence such as: a) low expression of CD28 molecule; b) telomere shortening and c) increase production of proinflammatory cytokines. The study was carried out in CD8 + T cells from 14 patients transplanted without clinical evidences of acute renal rejection, 14 patients kidney transplanted with clinical and anatomopathological evidences of acute renal rejection, 8 healthy controls. The results shown that in peripheral blood and renal biopsy of patients with acute renal rejection there is a significant increment of the population of T cells CD28-CD8+, with short telomere length, as compared with healthy controls and patients without acute renal rejection. The presence of senescent cells was associated with high levels of IL-10 and IFN-Y in plasma and urine. In conclusion our study suggest that the CD8 + T cells of patients with acute renal rejection suffer a process of replicative senescence.


Asunto(s)
Linfocitos T CD8-positivos/fisiología , Rechazo de Injerto/inmunología , Trasplante de Riñón/inmunología , Adulto , Anciano , Antígenos CD28 , Senescencia Celular , Femenino , Humanos , Interferón gamma/sangre , Interleucina-10/sangre , Masculino , Persona de Mediana Edad
10.
Kidney Int Suppl ; 68: S86-91, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9839290

RESUMEN

Cardiovascular instability continues to be one of the primary clinical problems in hemodialysis. Acetate buffer in dialysate is one of the factors that may induce hypotension. Since uremia may have a direct effect on the regulation of the cardiovascular system, the present study was designed to investigate the separate effects of uremia and acetate hemodialysis on blood pressure in anesthesized dogs, as well as the hemodynamic parameters determined by invasive cardiovascular monitoring. Animals were separated into four groups: (1) group I, hemodialysis with acetate in controls; (2) group II, hemodialysis with acetate in uremic dogs; (3) group III, hemodialysis with bicarbonate in controls; and (4) group IV, hemodialysis with bicarbonate in uremic dogs. Acute uremia was induced by bilateral ureteral ligation and a 90-minute hemodialysis (acetate or bicarbonate) procedure was performed 72 hours later. The results obtained in this study show that, compared with dogs with normal renal function, acute uremia resulted in an elevation in mean arterial pressure (MAP; 178 +/- 13 vs. 115 +/- 23 mm Hg, P < 0.01), which was associated with an increase in cardiac index (CI) and left ventricular stroke work index (LVSWI). In these dogs, the pulmonary capillary wedge pressure (PCWP; preload) and the systemic vascular resistance index (SVRI; afterload) were not different than controls. In uremic dogs, hemodialysis with acetate, but not with bicarbonate, decreased the MAP to values similar to controls. The decrease in MAP induced by acetate hemodialysis in uremic dogs was associated with a decrease in SVRI and PCWP. These results suggest that in dogs with acute uremia, acetate hemodialysis (HD) decreases myocardial contractility that was previously increased by a direct effect of uremia. In controls, acetate produced a moderate decrease in MAP that was the result of a mild decrease in CI and SVR. Since PCWP was not significantly decreased after acetate HD, the decrease in CI can be attributed to a mild decrease in myocardial performance. In conclusion, this study in dogs suggests that uremia enhances myocardial contractility directly. Acetate hemodialysis reduces this elevated myocardial contractility to normal values.


Asunto(s)
Acetatos/farmacología , Bicarbonatos/farmacología , Sistema Cardiovascular/efectos de los fármacos , Diálisis Renal , Uremia/fisiopatología , Animales , Presión Sanguínea/efectos de los fármacos , Soluciones para Diálisis/farmacología , Perros , Presión Esfenoidal Pulmonar/efectos de los fármacos , Volumen Sistólico/efectos de los fármacos , Sístole/fisiología , Uremia/terapia , Resistencia Vascular/efectos de los fármacos , Función Ventricular Izquierda
11.
Kidney Int Suppl ; 68: S135-9, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9839298

RESUMEN

Arterial hypertension, which represents a common problem in patients with renal transplant, contributes to the cardiovascular morbidity and mortality of these patients. The most usual immunosuppressive drugs (cyclosporine and FK-506) collaborate on the development of hypertension. Calcium channel blockers are the most habitually used antihypertensive drugs in this population, although its long-term hemodimamycs effects could be deleterious especially in transplanted patients with chronic graft nephropathy. Losartan, a specific blocker of angiotensin II (AT1) receptors, has demonstrated a potent antihypertensive effect with a good safety and tolerance profile. The glomerular effects of losartan could be useful in transplanted patients. The present open, prospective and multicenter study evaluated the efficacy and safety of losartan in the treatment of hypertension in a group of patients with a renal transplant. Seventy-six patients with systolic blood pressure > or = 140 and/or diastolic blood pressure > or = 90 mm Hg, and/or patients on therapy with one antihypertensive drug and related side effects were included. After inclusion, therapy with losartan 50 mg/24 hr was started, discontinuing the previous antihypertensive therapy and/or therapy which caused the side effects. At four weeks, if blood pressure (BP) was not controlled, hydrochlorothiazide 25 mg or furosemide 40 mg/24 hr was added. At baseline and at weeks 2, 4, 8 and 12, the following parameters were monitored: BP, creatinine, hematocrit, hemoglobin, glucose, ions, uric acid, cholesterol, triglycerides, bilirubin, SGOT, SGPT, GGT, LDH, calcium, phosphate, alkaline phosphatase, proteinuria, and both cyclosporine and FK-506 levels in whole blood. Sixty-seven patients completed the 12-week study period. Mean blood pressure decreased from 113 +/- 10 to 102 +/- 9 mm Hg at the end of the study (P < 0.0001); 38 of the 67 patients (56.7%) who completed the study had a SBP lower than 140 mm Hg and a DBP lower than 90. These blood pressures were obtained in 30 patients on monotherapy with losartan (78.9%). Proteinuria decreased significantly at week 4 and was confirmed at week 12, especially in patients with proteinuria > or = 300 mg/24 hr. Nine patients were withdrawn during the study period for different reasons. Serum creatinine showed a slight, non-clinically significant increase at week 4, remaining stable until the end of the study. Two patients developed a mild normocytic anemia, and three others presented a mild impairment of pre-existent anemia. No interactions with cyclosporine or FK-506 were described. These results indicate that losartan is effective in reducing BP in hypertensive patients with a renal transplant. It has a good tolerance profile and does not interfere with immunosuppressive therapy.


Asunto(s)
Antihipertensivos/administración & dosificación , Hipertensión Renal/tratamiento farmacológico , Trasplante de Riñón , Losartán/administración & dosificación , Adulto , Presión Sanguínea , Ciclosporina/administración & dosificación , Interacciones Farmacológicas , Femenino , Humanos , Inmunosupresores/administración & dosificación , Fallo Renal Crónico/cirugía , Masculino , Complicaciones Posoperatorias/tratamiento farmacológico , Tacrolimus/farmacología
12.
Artículo en Inglés | MEDLINE | ID: mdl-8992494

RESUMEN

Nitric oxide (NO) is formed in the endothelium by the constitutive enzyme NO synthase from the substrate amino acid L-arginine. As an endogenous vasodilator it contributes to renal arteriolar tone and modulates relaxation of the mesangium, thus contributing to regulation of glomerular microcirculation. NO also plays a role in regulating renal sodium excretion and renin release. It has antiplatelet and antithrombogenic effects and thus helps prevent thrombosis within the glomerular capillaries. In sepsis and sepsis-related syndromes, NO has a renoprotective role in that it aids in maintaining renal vasodilation and inhibiting platelet adhesion and aggregation. More knowledge of these effects may lead to the design of therapeutic interventions for preventing glomerular injury.


Asunto(s)
Endotelio Vascular/fisiología , Enfermedades Renales/fisiopatología , Óxido Nítrico/fisiología , Animales , Humanos , Natriuresis , Óxido Nítrico/biosíntesis
13.
Clin Nutr ; 19(5): 371-3, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11031078

RESUMEN

Two young females with severe morbid obesity presented with Wernicke's syndrome after Roux-en-Y gastro-jejunum bypass had been performed. The first patient had recurrent vomiting and dyplopia two months post-surgery. Physical examination indicated bilateral ophthalmoparesia with conserved convergence and ataxia. The second patient had frequent vomiting episodes over the previous three months together with lower limb hypotonia, myoclonia and generalised tonicoclonic seizures on two occasions within one year of surgery. In both cases routine blood test, ion levels (sodium, potassium, calcium, phosphates), electroencephalogram and CT scan were normal. Thiamine therapy was instigated on the basis of clinical intuition and the first patient achieved complete remission within 24 hours while the second improved gradually in that two years later only mild lower limb hypotonia and a slight cognitive deficit remains. Erythrocyte transketolase activity determinations were abnormal on two separate occasions for this second patient. Vitamin B1 determinations were not available for the first patient. In conclusion, the restriction in energy intake and the persistent vomiting together with malabsorption induced by the surgical intervention could explain the vitamin deficiency causing Wernicke's encephalopathy. This indicates a need for close monitoring and systematic vitamin supplementation in those patients who undergo bariatric surgery.


Asunto(s)
Anastomosis en-Y de Roux/efectos adversos , Derivación Gástrica/efectos adversos , Obesidad Mórbida/cirugía , Deficiencia de Tiamina/etiología , Tiamina/uso terapéutico , Encefalopatía de Wernicke/tratamiento farmacológico , Adulto , Suplementos Dietéticos , Femenino , Gastroplastia/efectos adversos , Humanos , Obesidad Mórbida/complicaciones , España , Tiamina/administración & dosificación , Deficiencia de Tiamina/tratamiento farmacológico , Encefalopatía de Wernicke/etiología
14.
Transplant Proc ; 35(5): 1701-3, 2003 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12962764

RESUMEN

This study was designed to assess the efficacy and safety of two immunosuppressant regimens in kidney transplantation based on the administration of tacrolimus-one of them with tacrolimus, azathioprine, and corticosteroids (n=239) and the other with tacrolimus, and corticosteroids (n=236). After completing the initial 3-month study, the patients remaining in the study (197 and 195, respectively) were assessed for 3 years. The incidence of acute rejection (AR) episodes treated during this period was 28.8% with dual-drug therapy and 29.7% with triple-drug therapy. Late AR: episodes between 4 and 36 months were scarce (3.3% in dual and 4.2% in triple therapy). Chronic rejection incidence was 7.7% and 8.9%, respectively. The patients who experienced AR episodes during the first 3 months developed chronic rejection more frequently than those who did not suffer AR. Patient survival at 3 years was 95% vs 95.6%, and graft survival was 86.6% vs 86.5% (NS). Doses and blood levels of tacrolimus were similar in the two groups. Adverse effects were similar among both treatment groups. Median SCr was 123.8 micromol/L vs 114.9 micromol/L in patients who did experience AR: 145.9 micromol/L vs 132.6 micromol/L in those with early AR; and 194.5 micromol/L vs 152 micromol/L in those who presented with late AR. Need for de novo posttransplant insulin was 4.2% in the dual-drug group and 3.8% in the triple-drug cohort. These results demonstrate that, after 3 years of follow up, there were similar efficacy data among the dual- and triple-drug regimens. Thus, addition of azathioprine does not contribute any advantage in the middle term.


Asunto(s)
Corticoesteroides/uso terapéutico , Azatioprina/uso terapéutico , Trasplante de Riñón/inmunología , Tacrolimus/uso terapéutico , Enfermedad Aguda , Enfermedad Crónica , Creatinina/sangre , Quimioterapia Combinada , Estudios de Seguimiento , Supervivencia de Injerto/inmunología , Supervivencia de Injerto/fisiología , Humanos , Inmunosupresores/uso terapéutico , Incidencia , Italia , Trasplante de Riñón/mortalidad , Trasplante de Riñón/fisiología , Recurrencia , España , Análisis de Supervivencia , Factores de Tiempo
15.
J Laparoendosc Adv Surg Tech A ; 8(2): 105-8, 1998 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9617972

RESUMEN

Morgagni's hernias represent between 2 and 4% of the whole of nontraumatic diaphragmatic hernias in the adult, and the treatment (even with minimal symptoms) is always with surgery. We present the case of a 50-year-old woman with an oppressive, postprandial discomfort in the right side of her thorax and with increased pain when supine. The x-ray examination indicated a large portion of transverse colon inside the thoracic cavity. Once the diagnosis of Morgagni's hernia had been obtained, she was scheduled for laparoscopic surgery to reduce the hernia and to reconstruct the defect of the diaphragm using a polypropylene mesh.


Asunto(s)
Hernia Diafragmática/cirugía , Hernias Diafragmáticas Congénitas , Laparoscopía , Femenino , Hernia Diafragmática/diagnóstico por imagen , Humanos , Persona de Mediana Edad , Polipropilenos , Radiografía , Mallas Quirúrgicas
16.
Hum Exp Toxicol ; 13(2): 135-9, 1994 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-7908811

RESUMEN

The relative effectiveness of deferoxamine (DFO), 1,2-dimethyl-1,3-hydroxypyrid-4-one (L1), and citric and succinic acids in mobilizing and promoting excretion of aluminium (Al) were compared in female uraemic rats which had previously received aluminium nitrate nonahydrate i.p. in a daily dose of 45 mg kg-1 for 3 weeks (5 days/week). Chelators were administered s.c. at doses equal to one-eighth of their respective LD50 for five days. L1 was also given p.o. in doses of 200 mg kg-1 day-1. Total urines were collected 24 h after each chelator administration. Total urinary Al excreted over the 5-day period, expressed as mg kg-1, were: controls, 3.4; DFO-treated, 4.5 (P < 0.05); citric acid-treated, 3.7; and succinic acid-treated, 2.7. Although the daily amounts of Al excreted into urine by L1-treated rats were significantly higher (P < 0.001) than those of the controls, most animals died during the period of treatment. Measurements of Al in selected tissues 24 h after the last administration of each chelator revealed that none of the compounds significantly altered the Al concentration in bone, kidney, and brain, whereas only DFO and succinic acid significantly reduced the levels of Al in spleen. Moreover, L1 (given s.c. or p.o.) and citric acid treatment led to a significant reduction in the liver Al burden. These results indicate the need for further investigations to determine the toxicity and the therapeutical safety margins of L1.


Asunto(s)
Aluminio/orina , Quelantes/farmacología , Piridonas/farmacología , Uremia/metabolismo , Aluminio/farmacocinética , Animales , Citratos/farmacología , Ácido Cítrico , Deferiprona , Deferoxamina/farmacología , Femenino , Inyecciones Intraperitoneales , Ratas , Ratas Sprague-Dawley , Succinatos/farmacología , Ácido Succínico , Distribución Tisular
17.
Eur J Pediatr Surg ; 13(6): 425-8, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14743335

RESUMEN

A hepatodiaphragmatic interposition of the colon, known as Chilaiditi's sign, is usually discovered by chance during the study of another event, given that its presentation is normally asymptomatic. When this finding is accompanied by clinical symptoms, either intermittent or persistent, it is known as Chilaiditi syndrome. It may be associated with intestinal obstruction due to twisting. The association of Chilaiditi syndrome and transverse colon volvulus is exceptional. To date only three cases have been reported, all in adult males. Among the common predisposing factors were anatomical alterations of the intestine such as elongation of the colon and a history of prior abdominal surgery. The clinical symptoms were due to the intestinal obstruction. We present the first description in the paediatric population of an association of transverse colon volvulus and Chilaiditi syndrome whose predisposing factors, clinical symptoms and treatment differed from those reported in the non-paediatric cases published to date.


Asunto(s)
Colon/anomalías , Enfermedades del Colon/complicaciones , Obstrucción Intestinal/complicaciones , Niño , Colon/patología , Dilatación Patológica , Humanos , Masculino , Síndrome
18.
Arch Bronconeumol ; 35(7): 317-23, 1999.
Artículo en Español | MEDLINE | ID: mdl-10439128

RESUMEN

OBJECTIVES: To study the prevalence and intensity of smoking among school-age children in Seville by sex, age and type of population, as well as to examine expectations of future smoking. METHODS: This study was part of a school anti-smoking campaign. The students completed an anonymous questionnaire based on the one formulated by the World Health Organization on population attitudes and habits. RESULTS: Of 895 school-age subjects surveyed, 879 questionnaires were valid (428 boys and 451 girls). Ages ranged from 12 to 19 years (mean for boys: 15.4 +/- 1.6 years; for girls 14.6 +/- 1.5 years; p < 0.01). As many as 300 girls (67%) and 278 boys (65%) reported having tried a cigarette at some time. Active smoking was reported by 35% (16% occasionally and 19% daily) with no significant differences between boys and girls. The number of smokers increased with age, coming to represent more than half of subjects over 16 years of age, the proportion being even higher for girls aged 14 years and older. Smoking became well established at age 14 or older for most subjects. More rural than urban or large town dwellers reported smoking. The mean number of cigarettes smoked was higher for boys (8.7 +/- 7.4) than for girls (6.4 +/- 6.2) (p < 0.01). We found differences in boys' and girls' future expectations of smoking, as well as differences between habitual and occasional smokers, the latter group being less certain about whether to continue smoking in the future or not.


Asunto(s)
Prevención del Hábito de Fumar , Fumar/epidemiología , Adolescente , Niño , Femenino , Promoción de la Salud , Humanos , Masculino , Prevalencia , Encuestas y Cuestionarios
19.
Nutr Hosp ; 28 Suppl 2: 23-30, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23834043

RESUMEN

Diabetes mellitus (DM) is a public health problem with a prevalence of 345 million people worldwide that it may double by the year 2030 and have a high costs and mortality. Gastrointestinal surgery is accepted as a form of treatment that was already suggested for obese in 1987 by Pories, confirmed for obese patients by the metaanalysis of Buchwald and the direct comparison of gastric bypass with medical treatment in the study of Schauer that demonstrate a 4 fold greater resolution rate of DM with surgery. Improvement occurs immediately after surgery, before the patients lose weight in with BMI > 35; but there is doubt if the existent evidence is enough to extrapolate these results to patients with BMI < 35 and especially with BMI < 30, in spite that four reviews in patients with this BMI and DM2 demonstrated the same results when stomach, duodenum and part of jejunum is bypassed as happen gastric bypass (better results with this of one anastomosis than of two anastomosis, Roux-en-Y) BPD. For patients with a BMI between 30 and 35 restrictive techniques: LAGB and SGL are good but not better than the mixed: RYGB, BAGUA, or SG-DJB with remission from 60 to 100%, minor in the derivative: BPD and above on the IID with a 81% of remission. There are no differences in the metabolic control in comparison to the obese, It is progressively better with DJB, SDS, IID and BAGUA especially in patients who do not require insulin, have less time with disease, have normal C peptide levels, and not so much relation with the initial BMI that is only important to decide the degree of restriction. Although several mechanisms has been suggested for explaining these results such as caloric intake, hormonal changes, bypass of the anterior or early stimulation of posterior intestine, fundectomy, intestinal gluconeogenesis and others, new ones will appear in the near future.


La diabetes mellitus (DM) es un problema de salud pública, con una prevalencia de 345 millones de personas, que puede duplicarse para el año 2030 y con importante repercusión en costes y mortalidad. La cirugía gastrointestinal es aceptada como una forma de tratamiento sugerida en obesos desde 1987 por Pories, y confirmada por el meta-análisis de Buchwald y la comparación directa del bypass gástrico con el mejor tratamiento médico en el estudio de Schauer que pone de manifiesto un índice de remisión 4 veces mayor con la cirugía. La mejoría ocurre inmediatamente después de la cirugía, antes de la pérdida de peso en pacientes con IMC > 35; pero hay duda si la evidencia existente es suficiente para extrapolar estos resultados a pacientes con IMC < 35 y especialmente con IMC < 30, a pesar de existir cuatro revisiones en pacientes con este IMC y DM2 que demuestran los mismos resultados que en obesos cuando se puentea estómago, duodeno y parte del yeyuno como pasa en el bypass gástrico y la DBP. Para pacientes con IMC entre 30 y 35 las técnicas restrictivas: BGAL Y GVL son buenas pero no superiores a las mixtas: BGYR, BAGUA o GV-BDY con remisión desde 60 a 100%, menor en las derivativas: DBP y mayor en la IID con un 81% de remisión. En pacientes con sobrepeso no existen diferencias en el control metabólico respecto a los obesos. Es progresivamente mejor con DBP, CDC, IID y BAGUA sobre todo en pacientes que no requieren insulina, tienen menos tiempo con la enfermedad o con un nivel de peptido C normal, factores determinantes y no así el IMC inicial que sólo influye en el volumen de restricción. Aunque se han sugerido distintos mecanismos para explicar los resultados como ingesta calórica, hormonales, teoría del intestino anterior o posterior, fundectomía , neoglucogénesis intestinal y otros, aparecerán más en un futuro no lejano.


Asunto(s)
Cirugía Bariátrica/métodos , Índice de Masa Corporal , Diabetes Mellitus Tipo 2/cirugía , Derivación Gástrica , Humanos
20.
Exp Clin Endocrinol Diabetes ; 121(2): 119-24, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23426707

RESUMEN

BACKGROUND: Lipocalin 2 (LCN2) has been related to obesity, insulin resistance and metabolic disturbance. However, its relation with non alcoholic fatty liver disease (NAFLD) has hardly been studied. METHODS: We examined LCN2 circulating levels and its protein and gene expression in liver from women with severe obesity and NAFLD. We analyzed the liver histology of 59 white severely obese women (BMI ≥40 Kg/m²): 15 subjects presented normal liver histology or non-significant liver disease (NL), 18 simple steatosis (SS) and 26 non alcoholic steatohepatitis (NASH). We determined the anthropometric and metabolic features of the women. LCN2 levels were determined by an ELISA and liver mRNA expression by real time RT-PCR. We also studied LCN2 expression in HepG2 liver cells under various inflammatory stimuli. RESULTS: Liver LCN2 protein and gene expression were higher in NAFLD than in obese with NL. Liver LCN2 gene expression correlated with SS (r=0.351, p=0.016), and its protein expression correlated with NASH (r=0.705, p=0.003). LCN2 expression was detected in HepG2 cells after the administration of TNFα, IL6, resistin or adiponectin. LCN2 expression was induced by TNFα, IL6 and resistin. CONCLUSIONS: Liver LCN2 is related to NAFLD in severely obese women. Up-regulation of LCN2 expression is detected in HepG2 cells after exposure to TNFα, IL6 and resistin. These results suggest that LCN2 expression is induced under liver harmful conditions.


Asunto(s)
Proteínas de Fase Aguda/metabolismo , Hígado Graso/metabolismo , Lipocalinas/metabolismo , Hígado/metabolismo , Obesidad Mórbida/complicaciones , Proteínas Proto-Oncogénicas/metabolismo , Regulación hacia Arriba , Proteínas de Fase Aguda/genética , Adulto , Biopsia , Índice de Masa Corporal , Estudios de Cohortes , Estudios Transversales , Citocinas/metabolismo , Hígado Graso/complicaciones , Hígado Graso/inmunología , Hígado Graso/patología , Femenino , Células Hep G2 , Humanos , Lipocalina 2 , Lipocalinas/sangre , Lipocalinas/genética , Hígado/inmunología , Hígado/patología , Cirrosis Hepática/etiología , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico , Obesidad Mórbida/cirugía , Proteínas Proto-Oncogénicas/sangre , Proteínas Proto-Oncogénicas/genética , ARN Mensajero/metabolismo , Resistina/metabolismo , España
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA